71.39
-2.93(-3.94%)
Currency In USD
| Previous Close | 74.32 |
| Open | 73.16 |
| Day High | 74.15 |
| Day Low | 70.81 |
| 52-Week High | 84.94 |
| 52-Week Low | 28.33 |
| Volume | 2.29M |
| Average Volume | 2.92M |
| Market Cap | 13.84B |
| PE | -18.89 |
| EPS | -3.78 |
| Moving Average 50 Days | 73.39 |
| Moving Average 200 Days | 58.5 |
| Change | -2.93 |
If you invested $1000 in BridgeBio Pharma, Inc. (BBIO) since IPO date, it would be worth $2,570.24 as of March 11, 2026 at a share price of $70.81. Whereas If you bought $1000 worth of BridgeBio Pharma, Inc. (BBIO) shares 5 years ago, it would be worth $994.24 as of March 11, 2026 at a share price of $70.81.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
BBP-418 Demonstrates Consistent Efficacy and Favorable Safety Profile in Phase 3 FORTIFY Interim Analysis in LGMD2I/R9
GlobeNewswire Inc.
3 hours ago
- Phase 3 FORTIFY interim analysis results presented in a late-breaking oral presentation at MDA highlight the broad and consistent efficacy of BBP-418 across key clinical endpoints and prespecified subgroups - Early separation from placebo observed
BridgeBio to Present Additional Data from the Phase 3 FORTIFY Trial at the 2026 MDA Clinical & Scientific Conference
GlobeNewswire Inc.
Mar 04, 2026 12:30 PM GMT
PALO ALTO, Calif., March 04, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, announced today that additional data fro
BridgeBio to Participate in March Investor Conferences
GlobeNewswire Inc.
Feb 23, 2026 12:30 PM GMT
PALO ALTO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a biopharmaceutical company focused on developing medicines for genetic conditions, today announced that members of its manag